Ignite Creation Date:
2024-05-05 @ 12:06 PM
Last Modification Date:
2024-10-26 @ 9:20 AM
Study NCT ID:
NCT00249808
Status:
COMPLETED
Last Update Posted:
2018-03-20
First Post:
2005-11-04
Brief Title:
A Study of Efalizumab in Participants With Moderate to Severe Chronic Psoriasis Who Have Failed Have a Contraindication to or Are Intolerant of Other Systemic Therapies
Sponsor:
Merck KGaA Darmstadt Germany
Organization:
Merck KGaA Darmstadt Germany
Study Overview
Official Title:
A Multicentre Open Label Phase IIIbIV Study of Subcutaneously Administered Efalizumab in the Treatment of Adult Patients With Moderate to Severe Chronic Plaque Psoriasis Who Have Failed to Respond to or Who Have a Contraindication to or Are Intolerant to Other Systemic Therapies Including Ciclosporin Methotrexate and PUVA
Status:
COMPLETED
Status Verified Date:
2017-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a Phase IIIbIV open label multicentre study of efalizumab anti cluster of differentiation CD 11a recombinant human monoclonal antibody in participants with moderate to severe plaque psoriasis who have failed to respond to have a contraindication to or are intolerant to other systemic therapies including ciclosporin methotrexate and psoralen and ultraviolet A phototherapy PUVA
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| Control II Study | None | None | None |